Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • AZD0156: Illuminating ATM Kinase Inhibition for Metabolic...

    2025-09-27

    AZD0156: Illuminating ATM Kinase Inhibition for Metabolic Targeting in Cancer Research

    Introduction

    The intersection of genomic instability and metabolic reprogramming is a defining feature of cancer biology. Recent advances in targeted therapeutics have spotlighted the ataxia telangiectasia mutated (ATM) kinase as a pivotal regulator of both DNA double-strand break repair and metabolic adaptation. AZD0156 (CAS: 1821428-35-6) stands at the forefront as a potent, selective, and orally bioavailable ATM kinase inhibitor. Unlike prior reviews that predominantly focus on either DNA damage response or synthetic lethality, this article synthesizes emerging evidence to illuminate how AZD0156 unveils actionable metabolic vulnerabilities in cancer cells and redefines checkpoint control modulation as a therapeutic strategy. We integrate mechanistic details, cutting-edge research, and practical considerations to provide a comprehensive resource for advanced cancer therapy research.

    ATM Kinase: Guardian of Genomic Stability and Metabolic Homeostasis

    The Central Role of ATM in DNA Damage Response

    ATM kinase, a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, orchestrates the cellular response to DNA double-strand breaks. Upon sensing DNA lesions, ATM triggers phosphorylation cascades that activate checkpoint control, facilitate DNA repair, and maintain genomic stability. Dysfunctional ATM signaling is tightly linked to tumorigenesis, underscoring its importance as a therapeutic target. Selective ATM inhibition thus offers a means to sensitize cancer cells to genotoxic stress while potentially exploiting metabolic dependencies unique to tumor environments.

    ATM and Metabolic Adaptation: Beyond Genomic Maintenance

    Beyond its canonical role in DNA repair, ATM is increasingly recognized for its influence on cellular metabolism. Loss or inhibition of ATM signaling can reprogram nutrient uptake and utilization pathways in cancer cells. Specifically, ATM suppression drives metabolic adaptation through the induction of macropinocytosis—a process by which cells non-selectively engulf extracellular nutrients to survive under nutrient-limited conditions. This was elegantly demonstrated in a recent study (Huang et al., 2023), where ATM inhibition was shown to increase macropinocytic activity, promoting cancer cell survival in harsh microenvironments.

    Mechanism of Action of AZD0156: Potent and Selective ATM Inhibition

    Chemical and Pharmacological Profile

    AZD0156 (SKU: B7822) is a small-molecule ATM kinase inhibitor characterized by:

    • Potency: Sub-nanomolar inhibitory activity against cellular ATM signaling.
    • Specificity: Over 1000-fold selectivity versus other PIKK family kinases (e.g., ATR, DNA-PK).
    • Oral Bioavailability: Enables in vivo studies and translational research.
    • Chemical Properties: Molecular weight 461.56 g/mol, formula C26H31N5O3, soluble in DMSO and ethanol, supplied at >98% purity.
    • Quality Control: HPLC and NMR verification, shipped with Blue Ice for optimal stability.

    These attributes position AZD0156 as a research-grade tool for dissecting ATM-dependent pathways in cancer biology.

    Disrupting DNA Double-Strand Break Repair and Checkpoint Control

    AZD0156 achieves its effects by binding to the kinase domain of ATM, blocking the phosphorylation of downstream effectors such as Chk2, p53, and H2AX. This results in compromised DNA damage checkpoint control, accumulation of DNA lesions, and ultimately increased cancer cell susceptibility to DNA-damaging agents. When administered in combination with chemotherapeutics or radiotherapy, AZD0156 enhances antitumor efficacy by abrogating the DNA repair capacity of tumor cells—an approach validated in preclinical cancer models.

    ATM Inhibition and Metabolic Vulnerabilities: New Frontiers for Cancer Therapy Research

    Macropinocytosis as a Survival Mechanism

    While previous articles—such as "AZD0156: Unlocking ATM-Inhibited Metabolic Vulnerabilities"—have outlined how ATM inhibition exposes metabolic weaknesses, our analysis delves deeper into the mechanistic underpinnings and experimental strategies to target these adaptations. The study by Huang et al. (2023) revealed that ATM inhibition induces macropinocytosis, allowing cancer cells to scavenge extracellular amino acids and proteins under nutrient deprivation. Strikingly, simultaneous blockade of ATM and macropinocytosis suppressed tumor cell proliferation and triggered apoptosis both in vitro and in vivo.

    Branched-Chain Amino Acid (BCAA) Uptake and mTORC1 Signaling

    The metabolic adaptation to ATM inhibition is characterized by increased uptake of branched-chain amino acids (BCAAs), which serve as critical substrates for protein synthesis and mTORC1 pathway activation. Supplementation of BCAAs was shown to curb macropinocytic activity, highlighting a feedback loop between nutrient availability and metabolic scavenging. The metabolomic analysis of tumor microenvironments further documented a depletion of BCAAs in ATM-inhibited tumors, suggesting that AZD0156 can be leveraged to create metabolic bottlenecks that sensitize cancer cells to nutrient deprivation strategies.

    Checkpoint Control Modulation and Synthetic Lethality

    ATM inhibition by AZD0156 not only impairs DNA repair but also disrupts cell cycle checkpoints, rendering tumor cells reliant on alternative DNA damage response pathways. This sets the stage for synthetic lethality approaches—whereby concurrent inhibition of ATM and compensatory mechanisms (e.g., ATR, PARP) leads to selective cancer cell death. While articles like "AZD0156: Advancing ATM Kinase Inhibition for Synthetic Lethality" have explored these strategies, our focus is on integrating metabolic and checkpoint vulnerabilities for combinatorial targeting.

    Comparative Analysis: AZD0156 Versus Alternative ATM Inhibition Approaches

    Potency and Selectivity in the PIKK Family

    AZD0156 distinguishes itself from other ATM inhibitors by its sub-nanomolar cellular potency and remarkable selectivity. Many first-generation ATM inhibitors exhibit off-target activity against related kinases such as ATR and DNA-PK, complicating interpretation of experimental results. AZD0156’s >1000-fold selectivity enables precise interrogation of ATM-dependent biology, minimizing confounding effects from other PIKK family members.

    In Vivo Compatibility and Oral Bioavailability

    Unlike some tool compounds restricted to in vitro use, AZD0156’s oral bioavailability facilitates translational research in animal models, expanding its utility for preclinical validation of ATM-targeted strategies. Its chemical stability, purity standards, and well-documented pharmacology further support reproducibility and rigor in research applications.

    Advanced Applications in Cancer Therapy Research

    Modeling DNA Damage Response Inhibition and Combination Therapies

    AZD0156 is widely employed to dissect the DNA damage response, particularly in studies evaluating combination therapies with DNA-damaging agents (e.g., topoisomerase inhibitors, ionizing radiation). By selectively inhibiting ATM, researchers can determine the contribution of checkpoint control and DNA repair pathways to therapeutic resistance in various cancer models. Recent data indicate that AZD0156 can also potentiate the effects of PARP inhibitors, supporting its role in synthetic lethality strategies for tumors with homologous recombination repair deficiencies.

    Exploiting Metabolic Adaptation for Therapeutic Gain

    Building on insights from Huang et al. (2023), AZD0156 serves as a platform to investigate how ATM inhibition-induced macropinocytosis and altered BCAA metabolism create exploitable vulnerabilities. Researchers can employ AZD0156 to:

    • Characterize metabolic fluxes and nutrient uptake in ATM-inhibited cancer cells
    • Test the efficacy of dual targeting (e.g., ATM plus macropinocytosis inhibitors) in suppressing tumor growth
    • Identify biomarkers predictive of metabolic adaptation in response to ATM inhibition

    Precision Oncology and Patient Stratification

    The specificity of AZD0156 as an ATM kinase inhibitor enables refined preclinical models and supports the development of biomarker-driven clinical trials. Ongoing early-phase studies are assessing the safety and preliminary efficacy of AZD0156 in advanced cancer patients, with particular interest in tumors exhibiting ATM loss or DNA repair defects.

    How This Article Advances the Field

    While previous articles, such as "AZD0156: Redefining ATM Kinase Inhibition Through Metabolic Adaptation", have detailed how ATM inhibition drives metabolic changes, this article uniquely integrates recent mechanistic data to propose actionable experimental strategies for targeting metabolic adaptation alongside DNA repair inhibition. Our approach emphasizes not only understanding but also exploiting the dual role of ATM in genomic and metabolic regulation for next-generation cancer therapy research.

    Practical Considerations and Product Handling

    For optimal results in the laboratory, AZD0156 should be dissolved in DMSO at concentrations ≥23.1 mg/mL (with gentle warming) or in ethanol (≥5.49 mg/mL). It is insoluble in water. Store the compound at -20°C, and use prepared solutions promptly, as long-term storage is not recommended. Each batch is supplied with HPLC and NMR purity data (typically >98%), ensuring high experimental reproducibility. For further details, refer to the product page for AZD0156.

    Conclusion and Future Outlook

    AZD0156 epitomizes the next generation of selective ATM kinase inhibitors for cancer research. Its dual impact on DNA double-strand break repair and metabolic adaptation enables investigators to probe—and potentially exploit—complex vulnerabilities in tumor cells. As mechanistic understanding deepens, particularly regarding the regulation of macropinocytosis and nutrient uptake, AZD0156 is poised to drive innovative therapeutic strategies combining DNA damage response inhibition with metabolic targeting. Researchers are encouraged to leverage AZD0156 for advanced applications in cancer therapy research, and to remain attuned to evolving insights that will shape the future of precision oncology.